SCHEMBL4569892

SCHEMBL4569892

CC(=O)c1sccc1NS(=O)(=O)c1ccccc1-c1cnc(C)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 1/20 0.44
KCNH2 Q12809 1/20 0.41
EDNRA P25101 5/20 0.41
EDNRB P24530 2/20 0.41
NPSR1 Q6W5P4 3/20 0.39
RXFP1 Q9HBX9 2/20 0.39
PRNP P04156 1/20 0.39
PPARG P37231 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
MAPK8 P45983 1/20 0.39
MAPK10 P53779 1/20 0.39
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
ALOX5AP P20292 3/20 0.37
FEN1 P39748 3/20 0.37
POLB P06746 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4569888 0.88 SLC10A6 (0.45) SLC10A6KCNH2EDNRAEDNRBNPSR1
SCHEMBL4569893 0.84 SLC10A6 (0.46) SLC10A6KCNH2EDNRAEDNRBNPSR1
SCHEMBL13552684 0.84 SLC10A6 (0.41) SLC10A6KCNH2EDNRAEDNRBNPSR1
SCHEMBL4569889 0.82 BRD4 (0.48) SLC10A6KCNH2NPSR1RXFP1PRNP
SCHEMBL4569890 0.78 EDNRA (0.45) SLC10A6EDNRAEDNRBBRD4
SCHEMBL4569891 0.74 PTGES2 (0.47) SLC10A6
SCHEMBL13552673 0.73 SLC10A6 (0.42) SLC10A6KCNH2EDNRAEDNRBNPSR1
SCHEMBL2158425 0.70 ACLY (0.54) SLC10A6KCNH2EDNRANPSR1HPGD
SCHEMBL4569877 0.69 TSHR (0.56) SLC10A6KCNH2NPSR1RXFP1LMNA
SCHEMBL13552623 0.69 SLC10A6 (0.42) SLC10A6KCNH2EDNRAEDNRBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed
US-8158789-B2 Arginine derivatives with NP-I antagonistic activity Ark Therapeutics Group Ltd. (GB) 2012-04-17 US disclosed
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 SLC10A6 1440/4885KCNH2 2004/4885EDNRA 18/4885
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 SLC10A6 1440/4885KCNH2 2004/4885EDNRA 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.